QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019

BACKGROUND: Observational studies have suggested increased arrhythmic and cardiovascular risk with the combination use of hydroxychloroquine (HCQ) and azithromycin in patients with coronavirus disease 2019 (COVID-19). OBJECTIVE: The arrhythmic safety profile of HCQ monotherapy, which remains under i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sridhar, Arun R., Chatterjee, Neal A., Saour, Basil, Nguyen, Dan, Starnes, Elizabeth A., Johnston, Christine, Green, Margaret L., Roth, Gregory A., Poole, Jeanne E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289101/
https://www.ncbi.nlm.nih.gov/pubmed/32835316
http://dx.doi.org/10.1016/j.hroo.2020.06.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289101/
https://www.ncbi.nlm.nih.gov/pubmed/32835316
http://dx.doi.org/10.1016/j.hroo.2020.06.002

Ejemplares similares